Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07141004 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)

StatusRecruiting
PhasePhase 4
Started2025-08-12
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate the safety and how well guselkumab treatment works (efficacy) in participants with psoriatic arthritis (PsA; a chronic, autoimmune form of arthritis that causes joint inflammation) who had inadequate response to standard therapies.

Amendment record

Amended 13 times since 2025-08-21; most recent filed 2026-08-27. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-27
Amendment Study Status v13
2026-07-30
Amendment Study Status, Contacts/Locations v12
2026-07-02
Amendment Study Status v11
2026-06-04
Amendment Study Status v10
2026-05-07
Amendment Study Status, Contacts/Locations v9
2026-04-09
Amendment Study Status, Contacts/Locations v8
2026-03-12
Amendment Study Status v7
2026-02-12
Amendment Study Status v6
2026-01-15
Amendment Study Status, Contacts/Locations v5
2025-12-18
Amendment Study Status, Contacts/Locations v4
2025-10-09
Amendment Study Status v3
2025-09-16
Amendment Study Status, Contacts/Locations v2
2025-09-11
Amendment Study Status v1
2025-08-21
Original filing
Trial Details
NCT Number NCT07141004
Lead Sponsor Johnson & Johnson Private Limited
Conditions Arthritis, Psoriatic
Enrollment 100 participants
Start Date 2025-08-12
Primary Completion 2027-06-05 (estimated)
Study Completion 2027-09-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-28